2025 Q4 -tulosraportti
19 päivää sitten
‧32 min
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 5 294 | - | - | ||
| 12 444 | - | - | ||
| 10 056 | - | - | ||
| 2 500 | - | - | ||
| 11 230 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 339 599 | 339 599 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 339 599 | 339 599 | 0 | 0 |
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 21.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.3. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 | ||
2024 Q4 -tulosraportti 20.3.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·1 päivä sittenUntil the company can clearly demonstrate through large studies precisely how, and especially why in terms of more effective treatment and savings, the product should be used, it will not be sold in larger numbers. The test costs a fortune compared to the existing one, and there is no medicine one can give in connection with acute kidney injury - so why exactly use it, when fluids and medication will already be regulated? The product, after almost 15 years available and attempted to be sold, would sell itself, where the opposite is still the case, if it both saved lives and resulted in savings, but that is far from documented. Should it succeed in documenting the effect in a few years, the major players can simply offer a similar product, as the patents begin to expire this year.
·1 päivä sittenK1000 I think it's strange that you start discussing Bioporto, on another stock's page. You are apparently in doubt whether I know Bioporto's path to an FDA approval for children. The short version of why Bioporto chose to split the NGAL test into two. One for children and one for adults. Bioporte had for an incredibly many years tried to get the NGAL test approved in the USA, as a combined test, but was rejected, with a standard text, that there was not enough evidence etc. Only when Antony became CEO, (he is a US citizen) did he get a dialogue with the FDA, and here the FDA suggested that if Bioporto were to have a chance of getting an approval, the test should be split into two, as it is today. The FDA stipulated that it should be the children's test they should run through a study first, if the FDA were to receive an application form. So it was not by Bioporto's good will or suggestion that the test was split into two, it was the FDA that suggested it, and it was the FDA that stipulated that it should be the test for children that they would look at first. When the FDA says jump, you ask how high. There are several webcasts where PME details the process with the FDA. You'll have to find them yourself on You tube.- ·1 päivä sittenMajor Shareholder Announcement https://www.globenewswire.com/news-release/2026/04/13/3272255/0/en/Major-Shareholder-Announcement.html
·1 päivä sittenDid anyone film the closing action, it looked like fiction with a marker inventing on flat before and on the landing, that's market-influencing, that's wrong, a single buyer, without a marker, could have landed it a quarter pct up, and not 8 pct down. - ·1 päivä sittenIf the new prime minister in Hungary ensures to release the money to Ukraine, as he has promised, then it's just a matter of time until the Russian troops withdraw, and Trump helps by closing the Strait of Hormuz. Yes, that will give a small bump in Denmark, in the short term.
- ·10.4.Bioporto has announced on LinkedIn that they are at a fair in Brazil where they have a stand. https://www.linkedin.com/company/bioporto-diagnostics-a-s/posts/?feedView=all
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
19 päivää sitten
‧32 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 päivä sittenUntil the company can clearly demonstrate through large studies precisely how, and especially why in terms of more effective treatment and savings, the product should be used, it will not be sold in larger numbers. The test costs a fortune compared to the existing one, and there is no medicine one can give in connection with acute kidney injury - so why exactly use it, when fluids and medication will already be regulated? The product, after almost 15 years available and attempted to be sold, would sell itself, where the opposite is still the case, if it both saved lives and resulted in savings, but that is far from documented. Should it succeed in documenting the effect in a few years, the major players can simply offer a similar product, as the patents begin to expire this year.
- ·1 päivä sittenK1000 I think it's strange that you start discussing Bioporto, on another stock's page. You are apparently in doubt whether I know Bioporto's path to an FDA approval for children. The short version of why Bioporto chose to split the NGAL test into two. One for children and one for adults. Bioporte had for an incredibly many years tried to get the NGAL test approved in the USA, as a combined test, but was rejected, with a standard text, that there was not enough evidence etc. Only when Antony became CEO, (he is a US citizen) did he get a dialogue with the FDA, and here the FDA suggested that if Bioporto were to have a chance of getting an approval, the test should be split into two, as it is today. The FDA stipulated that it should be the children's test they should run through a study first, if the FDA were to receive an application form. So it was not by Bioporto's good will or suggestion that the test was split into two, it was the FDA that suggested it, and it was the FDA that stipulated that it should be the test for children that they would look at first. When the FDA says jump, you ask how high. There are several webcasts where PME details the process with the FDA. You'll have to find them yourself on You tube.
- ·1 päivä sittenMajor Shareholder Announcement https://www.globenewswire.com/news-release/2026/04/13/3272255/0/en/Major-Shareholder-Announcement.html·1 päivä sittenDid anyone film the closing action, it looked like fiction with a marker inventing on flat before and on the landing, that's market-influencing, that's wrong, a single buyer, without a marker, could have landed it a quarter pct up, and not 8 pct down.
- ·1 päivä sittenIf the new prime minister in Hungary ensures to release the money to Ukraine, as he has promised, then it's just a matter of time until the Russian troops withdraw, and Trump helps by closing the Strait of Hormuz. Yes, that will give a small bump in Denmark, in the short term.
- ·10.4.Bioporto has announced on LinkedIn that they are at a fair in Brazil where they have a stand. https://www.linkedin.com/company/bioporto-diagnostics-a-s/posts/?feedView=all
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 5 294 | - | - | ||
| 12 444 | - | - | ||
| 10 056 | - | - | ||
| 2 500 | - | - | ||
| 11 230 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 339 599 | 339 599 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 339 599 | 339 599 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 21.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.3. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 | ||
2024 Q4 -tulosraportti 20.3.2025 |
2025 Q4 -tulosraportti
19 päivää sitten
‧32 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 21.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.3. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 | ||
2024 Q4 -tulosraportti 20.3.2025 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 päivä sittenUntil the company can clearly demonstrate through large studies precisely how, and especially why in terms of more effective treatment and savings, the product should be used, it will not be sold in larger numbers. The test costs a fortune compared to the existing one, and there is no medicine one can give in connection with acute kidney injury - so why exactly use it, when fluids and medication will already be regulated? The product, after almost 15 years available and attempted to be sold, would sell itself, where the opposite is still the case, if it both saved lives and resulted in savings, but that is far from documented. Should it succeed in documenting the effect in a few years, the major players can simply offer a similar product, as the patents begin to expire this year.
- ·1 päivä sittenK1000 I think it's strange that you start discussing Bioporto, on another stock's page. You are apparently in doubt whether I know Bioporto's path to an FDA approval for children. The short version of why Bioporto chose to split the NGAL test into two. One for children and one for adults. Bioporte had for an incredibly many years tried to get the NGAL test approved in the USA, as a combined test, but was rejected, with a standard text, that there was not enough evidence etc. Only when Antony became CEO, (he is a US citizen) did he get a dialogue with the FDA, and here the FDA suggested that if Bioporto were to have a chance of getting an approval, the test should be split into two, as it is today. The FDA stipulated that it should be the children's test they should run through a study first, if the FDA were to receive an application form. So it was not by Bioporto's good will or suggestion that the test was split into two, it was the FDA that suggested it, and it was the FDA that stipulated that it should be the test for children that they would look at first. When the FDA says jump, you ask how high. There are several webcasts where PME details the process with the FDA. You'll have to find them yourself on You tube.
- ·1 päivä sittenMajor Shareholder Announcement https://www.globenewswire.com/news-release/2026/04/13/3272255/0/en/Major-Shareholder-Announcement.html·1 päivä sittenDid anyone film the closing action, it looked like fiction with a marker inventing on flat before and on the landing, that's market-influencing, that's wrong, a single buyer, without a marker, could have landed it a quarter pct up, and not 8 pct down.
- ·1 päivä sittenIf the new prime minister in Hungary ensures to release the money to Ukraine, as he has promised, then it's just a matter of time until the Russian troops withdraw, and Trump helps by closing the Strait of Hormuz. Yes, that will give a small bump in Denmark, in the short term.
- ·10.4.Bioporto has announced on LinkedIn that they are at a fair in Brazil where they have a stand. https://www.linkedin.com/company/bioporto-diagnostics-a-s/posts/?feedView=all
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 5 294 | - | - | ||
| 12 444 | - | - | ||
| 10 056 | - | - | ||
| 2 500 | - | - | ||
| 11 230 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 339 599 | 339 599 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 339 599 | 339 599 | 0 | 0 |